Hepatitis C Virus-Like Particles Induce Virus–Specific Humoral and Cellular Immune Responses in Mice
Martin Lechmann(Roche (Switzerland)), Jake T. Liang(National Institutes of Health), John Vergalla, Jujin Satoi(National Institutes of Health), Kazumoto Murata(National Center for Global Health and Medicine), Thomas F. Baumert(National Institutes of Health)
Cited by 109
Related Papers
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
|Hepatology|2004|724
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
|Journal of Hepatology|2019|364
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
|Hepatology|2002|216
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)
|Journal of Biological Chemistry|2013|166